Kidney outcomes with semaglutide in obesity without diabetes (SELECT)

Evidence tier

Established · GLP-1 · CKM

Plain-language summary

In adults with obesity and cardiovascular disease but no diabetes, a prespecified secondary analysis found a lower composite kidney endpoint with semaglutide. This is a secondary kidney analysis within a cardiovascular-outcomes trial, not a dedicated kidney-outcome trial.

Key findings

  • Composite kidney endpoint: HR 0.78 (95% CI 0.63–0.96).
  • Endpoint included kidney death, chronic kidney replacement therapy, persistent eGFR <15, persistent ≥50% eGFR reduction, or persistent macroalbuminuria.

Population

Adults with overweight/obesity and established cardiovascular disease, without diabetes; semaglutide 2.4 mg weekly.

What this does not prove

A prespecified secondary analysis, not a dedicated kidney-outcome trial. It does not establish semaglutide as primary renoprotective therapy in non-diabetic obesity on its own.

Primary source

Colhoun HM, et al. Nat Med. 2024;30:2058–2066.
https://www.nature.com/articles/s41591-024-03015-5

Educational only

Paraphrased from the primary publication; not individual medical advice. Verify against the source before applying to care.